Company Description
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing’s syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.
In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial.
The company was incorporated in 1998 and is headquartered in Menlo Park, California.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 352 |
| CEO | Joseph Belanoff |
Contact Details
Address: 149 Commonwealth Drive Menlo Park, California 94025 United States | |
| Phone | 650 327 3270 |
| Website | corcept.com |
Stock Details
| Ticker Symbol | CORT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001088856 |
| CUSIP Number | 218352102 |
| ISIN Number | US2183521028 |
| Employer ID | 77-0487658 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, Chief Executive Officer and Director |
| Atabak Mokari | Chief Financial Officer and Treasurer |
| Sean Maduck | President of Endocrinology |
| Dr. William Guyer Pharm.D. | Chief Development Officer |
| Joseph Douglas Lyon | Chief Accounting and Technology Officer |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer |
| Amy Flood | Chief Human Resources and Communications Officer |
| Monica Tellado | President of Emerging Markets |
| Roberto W. Vieira | President of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 22, 2024 | 144 | Filing |
| Nov 22, 2024 | 144 | Filing |
| Nov 12, 2024 | 144 | Filing |
| Nov 1, 2024 | 144 | Filing |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 1, 2024 | 144 | Filing |
| Oct 1, 2024 | 144 | Filing |
| Sep 3, 2024 | 144 | Filing |
| Aug 26, 2024 | 144 | Filing |